For a blood-borne cancer therapeutic agent to be effective, it must cross the blood vessel
wall to reach cancer cells in adequate quantities, and it must overcome the resistance …

Cancer is still the leading cause of death globally. The approval of the therapeutic use of
monoclonal antibodies against immune checkpoint molecules, notably those that target the …

Existing nanoparticle-mediated drug delivery systems for glioma systemic chemotherapy
remain a great challenge due to poor delivery efficiency resulting from the blood brain …

Blood–brain barrier (BBB) strictly controls matter exchange between blood and brain, and
severely limits brain penetration of systemically administered drugs, resulting in ineffective …

Strategies for selectively imaging and delivering drugs to tumours typically leverage
differentially upregulated surface molecules on cancer cells. Here, we show that …

The expanding spectrum of both established and candidate oncogenic driver mutations
identified in non-small-cell lung cancer (NSCLC), coupled with the increasing number of …

Brain, the major organ of the central nervous system controls and processes most of body
activities. Therefore, the most aggressive brain tumor–glioblastoma and metastases from …

The blood-brain barrier (BBB) has long limited therapeutic access to brain tumor and
peritumoral tissue. In animals, MR-guided focused ultrasound (MRgFUS) with intravenously …

Brain metastasis represents a substantial source of morbidity and mortality in various
cancers, and is characterized by high resistance to chemotherapy. Here we define the role …

The endothelial cells lining the brain capillaries separate the blood from the brain
parenchyma. The endothelial monolayer of the brain capillaries serves both as a crucial …